53% of South Florida recovery residences completely prohibit buprenorphine, forcing residents to choose between evidence-based medication and stable housing

A 2024 secret shopper survey of 100 recovery residences in South Florida found that 53% completely prohibited buprenorphine use by residents, and nationally, less than half of residential recovery facilities allow people to remain on opioid maintenance medications like methadone or buprenorphine. Why it matters: people in early recovery from opioid use disorder who take FDA-approved medications are denied housing in the facilities specifically designed to support their recovery, so they must choose between stable housing and the medication that reduces their overdose death risk by 38-59%, so many discontinue medication to secure housing and subsequently relapse, so relapse without housing stability compounds into homelessness and repeated overdose, so the recovery housing system actively undermines the medical standard of care for the population it claims to serve. The structural root cause is that the recovery housing industry grew out of 12-step abstinence-only traditions that define recovery as complete sobriety from all substances, classifying FDA-approved medications like methadone and buprenorphine as 'substituting one drug for another,' and because recovery houses are largely unregulated with no federal licensing requirements, individual operators can impose medication bans without accountability, even though the HHS Assistant Secretary for Planning and Evaluation has documented this as a critical barrier to recovery.